Post-finasteride syndrome
An. bras. dermatol
;
95(3): 271-277, May-June 2020. tab
Article
in English
| LILACS, ColecionaSUS
| ID: biblio-1130879
ABSTRACT
Abstract Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects. Recently there have been reports of adverse drug-related reactions that persisted for at least three months after discontinuation of this drug, and the term post-finasteride syndrome arose. It includes persistent sexual, neuropsychiatric, and physical symptoms. Studies to date cannot refute or confirm this syndrome as a nosological entity. If it actually exists, it seems to occur in susceptible people, even if exposed to small doses and for short periods, and symptoms may persist for long periods. Based on currently available data, the use of 5α-reductase inhibitors in patients with a history of depression, sexual dysfunction, or infertility should be carefully and individually assessed.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Sexual Dysfunction, Physiological
/
Finasteride
/
5-alpha Reductase Inhibitors
Type of study:
Diagnostic study
/
Etiology study
/
Risk factors
Limits:
Humans
/
Male
Language:
English
Journal:
An. bras. dermatol
Year:
2020
Type:
Article
Institution/Affiliation country:
Universidade Federal de Minas Gerais/BR
Similar
MEDLINE
...
LILACS
LIS